Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof

A porcine respiratory and inactivation technology, applied in the field of inactivated mixed vaccines for porcine respiratory diseases

Inactive Publication Date: 2007-04-04
CHOONG ANG VACCINE LAB
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, no suitable vacci

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof
  • Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof
  • Inactivated mixed vaccine for porcine respiratory disease and the method of manufacturing thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] Example 1: Isolation and cultivation of viruses

[0027] For porcine Glasser's disease, in tryptic soy broth containing 45 μg / ml β-Nicotinamide adenine dinucleotide (β-NAD), 0.5% yeast extract, and 0.5% sucrose The S4 strain of Haemophilus parasuis and the S5 strain of Haemophilus parasuis (obtained from National Veterinary Research and Quarantine Service) were respectively cultured in (Tryptic Soy Broth, TSB) medium. The cultured strains were then isolated, lyophilized and cryopreserved at -80°C. The Mycoplasma hyopneumoniae J / 101 strain (obtained from the National Veterinary Research and Quarantine Service), which causes porcine enzootic pneumonia, was released and cultured in mycoplasma medium (Table 1). After isolation, the cultured Mycoplasma strains were lyophilized and cryopreserved at -80°C. Next, the Mycoplasma hyopneumoniae J / 101 strain was transferred to 1 / 3 volume of Mycoplasma medium (Table 1), and cultured for 7 to 10 days until the color of the medium t...

Embodiment 2

[0031] Example 2: Isolation and inactivation

[0032] For porcine Glasser's disease, each seed culture solution of Example 1 was released in TSB medium containing 45 μg / ml β-nicotinamide adenine dinucleotide (β-NAD), 0.5% yeast extract and Incubate at 37°C for 12 hours. The cultured strains were then isolated and concentrated, and inactivated using 0.3% formalin for 72 hours. For porcine enzootic pneumonia, M. hyopneumoniae J / 101 strain was transmitted in mycoplasma medium and cultured at 37°C for 7-10 days. Then, the cultured Mycoplasma strains were isolated and concentrated, and inactivated using 0.2% formalin at room temperature for 72 hours. For PRRS virus, porcine lung macrophages, porcine testis cell line (STL) cells or A-72 cells were inoculated with MN-HS or CNV-1 and cultured at 37°C for 3-5 days using a rotary culture system. When approximately 80% CPE was observed after virus inoculation, virus was isolated and inactivated using 0.1% formalin for 48 hours at room...

Embodiment 3

[0033] Embodiment 3: the preparation of inactivated mixed vaccine

[0034] The three antibodies of Example 2 were used to isolate strains, isolate pathogenic substances and inactivate various infection culture fluids. The total content of vaccine components is 30% (vol / vol) of the total mixed vaccine composition. The O.D. values ​​of each vaccine component are as follows: Haemophilus parasuis S4 (410 nm, O.D 0.45), Haemophilus parasuis S5 (410 nm, O.D 0.45), Mycoplasma hyopneumoniae J / 101 (410 nm, O.D 0.1) and PRRS MN-HS (10 6.0 TCID 50 / ml). After mixing the vaccine composition, filter through a copper mesh. Then, use aluminum hydroxide gel 20% (vol / vol) to adsorb the filtered composition, then additionally add oil adjuvant (IMS 1313NPR) 5% (vol / vol) and EDTA 0.14% (weight / volume), and Mixing was carried out at 1000 rpm for 30 minutes to obtain a mixture. Next, an amount of the mixture was dispensed into bottles and stored in a cold room at 2-7°C. The resulting mixed v...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to inactivated mixed vaccine for preventing porcine respiratory disease. The inactivated mixed vaccine of the present invention, which comprises a certain amount of inactivated Haemophilus parasuis S4 and S5, Mycoplasma hyopneumoniae , and PRRS virus, can effectively prevent porcine respiratory disease such as Glasser's disease, Swine enzootic pneumonia and PRRS. Further, the mixed vaccine of the present invention can prevent progress of the porcine respiratory disease to PRDC (Porcine Respiratory Disease Complex) and PMWS (Post-weaning Multisystemic Wasting Syndrome).

Description

technical field [0001] The present invention relates to vaccines for porcine respiratory diseases. In particular, the invention relates to inactivated mixed (combined) vaccines for porcine respiratory diseases. Background technique [0002] Swine respiratory disease has become a significant problem causing severe economic losses on farms. In particular, if the disease progresses to post-weaning multisystemic wasting syndrome (PMWS) characterized by neonatal death, persistent shrinkage and daily weight loss, or if the disease progresses to porcine respiratory syndrome ( porcine respiratory disease complex, PRDC), it produces extremely serious problems. In order to avoid and reduce the economic loss caused by the porcine respiratory disease (syndrome) infection, various vaccines have been used. However, because porcine respiratory disease has a variety of causes, vaccines for any one condition are not effective in many cases. At this point, several vaccine mixtures were de...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K39/295
CPCC12N2770/10034A61K39/12A61K39/0241A61K39/102A61K2039/521A61K2039/5252A61K2039/552A61K2039/55505A61K2039/55566A61K2039/70
Inventor 尹寅重李成珉俞成植
Owner CHOONG ANG VACCINE LAB
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products